Mounjaro vs. Zepbound | GLP-1 Clinics Nearby

Mounjaro vs. Zepbound: one molecule, two approvals

In short: Mounjaro and Zepbound are the same active ingredient from the same manufacturer. What separates them is the approved indication, and that difference decides almost everything about coverage.

Edited by

Taylor Rupe · Co-founder & CTO, Savo Group

B.S. in Computer Science, Oregon State University · B.A. in Psychology, University of Washington, Seattle

Shared ingredient

Tirzepatide

Mounjaro approved for

Type 2 diabetes

Zepbound approved for

Weight management

At a glance

Mounjaro vs. Zepbound at product level

The ingredient column is identical. Every practical difference sits in the rows below it.

Swipe horizontally to compare →

Mounjaro vs. Zepbound at product level. The ingredient column is identical. Every practical difference sits in the rows below it.
Product detail	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Receptor action	GIP and GLP-1	GIP and GLP-1
FDA-approved use	Type 2 diabetes	Chronic weight management
Second indication	None	Moderate to severe obstructive sleep apnea in adults with obesity
Prescribed for weight	Off-label	On-label

Table source:FDA product prescribing information

Same molecule, same manufacturer, different label

Mounjaro and Zepbound both contain tirzepatide, a single medication that acts on two receptors rather than one. They come from the same manufacturer. Comparing them is not like comparing two competing drugs; it is comparing two approvals of the same drug.

That is why the usual comparison questions do not apply here. There is no meaningful debate about which works better for weight, because the active ingredient is the same. The question worth asking is which product your prescription should name, and the answer is decided by what you are being treated for and by what your insurer will pay for.

The approved use is the whole difference

Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in eligible adults, and separately for moderate to severe obstructive sleep apnea in adults with obesity.

Prescribing Mounjaro for weight loss is off-label. That is lawful and it happens often, but it is the reason a plan that pays for Mounjaro when the diagnosis is diabetes may refuse the identical medication when the diagnosis is obesity.

Being treated for type 2 diabetes: Mounjaro is the on-label product.
Being treated for weight, with no diabetes diagnosis: Zepbound is the on-label product.
Diagnosed obstructive sleep apnea with obesity: Zepbound carries an indication Mounjaro does not.

An indication is not a claim about effectiveness. It describes what a manufacturer submitted evidence for and what the FDA reviewed, which is what an insurer reads.

What this means when you call a clinic

Ask which product the prescription will name before you pay for anything. A program quoting a low monthly price for tirzepatide is usually offering neither Mounjaro nor Zepbound, but a compounded preparation, which is a third category with a different regulatory status.

If a prior authorization is declined, ask the clinic what it does next. Switching between two brands of the same molecule is a conversation with the prescriber and the plan, not a reason to start over with a different clinic.

Common questions

Answers to clarify the comparison

Is Zepbound the same as Mounjaro?

They contain the same active ingredient, tirzepatide, from the same manufacturer. They are approved for different uses: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and for obstructive sleep apnea in adults with obesity.

Which one is prescribed for weight loss?

Zepbound is the on-label product for weight management. Mounjaro is sometimes prescribed off-label for weight, which is lawful and common, and is usually where insurance refusals come from.

Can I switch from Mounjaro to Zepbound?

That is a decision for the prescriber, and it is a common one when the reason for treatment is weight rather than diabetes. Because the molecule is the same, the conversation is usually about the indication on the prescription and what the plan will authorize.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.